CN104211700B - 咔啉羧酸类似物,其合成,纳米结构,抗肿瘤活性和应用 - Google Patents
咔啉羧酸类似物,其合成,纳米结构,抗肿瘤活性和应用 Download PDFInfo
- Publication number
- CN104211700B CN104211700B CN201310225687.4A CN201310225687A CN104211700B CN 104211700 B CN104211700 B CN 104211700B CN 201310225687 A CN201310225687 A CN 201310225687A CN 104211700 B CN104211700 B CN 104211700B
- Authority
- CN
- China
- Prior art keywords
- dimethyl
- dioxane
- carboline
- ylmethyl
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 230000000259 anti-tumor effect Effects 0.000 title abstract description 16
- 230000015572 biosynthetic process Effects 0.000 title description 3
- 238000003786 synthesis reaction Methods 0.000 title description 3
- 150000007942 carboxylates Chemical class 0.000 title description 2
- -1 benzyl ester Chemical class 0.000 claims abstract description 32
- 210000004881 tumor cell Anatomy 0.000 claims abstract description 8
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 7
- 238000002360 preparation method Methods 0.000 claims abstract description 7
- 239000002246 antineoplastic agent Substances 0.000 claims abstract description 3
- 229940041181 antineoplastic drug Drugs 0.000 claims abstract description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 21
- 238000000034 method Methods 0.000 claims description 19
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 7
- YVBFHJPJUNXZIH-UHFFFAOYSA-N 2-(2,2-dimethoxyethyl)-5,5-dimethyl-1,3-dioxane Chemical compound COC(OC)CC1OCC(C)(C)CO1 YVBFHJPJUNXZIH-UHFFFAOYSA-N 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 5
- XHTYQFMRBQUCPX-UHFFFAOYSA-N 1,1,3,3-tetramethoxypropane Chemical compound COC(OC)CC(OC)OC XHTYQFMRBQUCPX-UHFFFAOYSA-N 0.000 claims description 4
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 4
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 4
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 4
- 239000012286 potassium permanganate Substances 0.000 claims description 4
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 3
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 3
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 3
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 3
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical group OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 3
- SLCVBVWXLSEKPL-UHFFFAOYSA-N neopentyl glycol Chemical compound OCC(C)(C)CO SLCVBVWXLSEKPL-UHFFFAOYSA-N 0.000 claims description 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 2
- 238000009833 condensation Methods 0.000 claims description 2
- 230000005494 condensation Effects 0.000 claims description 2
- 230000008878 coupling Effects 0.000 claims description 2
- 238000010168 coupling process Methods 0.000 claims description 2
- 238000005859 coupling reaction Methods 0.000 claims description 2
- 230000007062 hydrolysis Effects 0.000 claims description 2
- 238000006460 hydrolysis reaction Methods 0.000 claims description 2
- KCUNTYMNJVXYKZ-JTQLQIEISA-N methyl (2s)-2-amino-3-(1h-indol-3-yl)propanoate Chemical compound C1=CC=C2C(C[C@H](N)C(=O)OC)=CNC2=C1 KCUNTYMNJVXYKZ-JTQLQIEISA-N 0.000 claims description 2
- 230000003647 oxidation Effects 0.000 claims description 2
- 238000007254 oxidation reaction Methods 0.000 claims description 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 229940124599 anti-inflammatory drug Drugs 0.000 claims 1
- 241000699670 Mus sp. Species 0.000 abstract description 19
- 230000000694 effects Effects 0.000 abstract description 18
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 8
- 230000004614 tumor growth Effects 0.000 abstract description 5
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 abstract description 4
- 230000004663 cell proliferation Effects 0.000 abstract description 4
- 244000309466 calf Species 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 210000001541 thymus gland Anatomy 0.000 abstract 1
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 62
- 150000001875 compounds Chemical class 0.000 description 30
- 235000001014 amino acid Nutrition 0.000 description 23
- 229940024606 amino acid Drugs 0.000 description 23
- 206010028980 Neoplasm Diseases 0.000 description 20
- 239000000243 solution Substances 0.000 description 20
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 19
- 238000005160 1H NMR spectroscopy Methods 0.000 description 16
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 16
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 15
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 15
- 239000000843 powder Substances 0.000 description 15
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 14
- 230000001629 suppression Effects 0.000 description 14
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 239000012980 RPMI-1640 medium Substances 0.000 description 7
- 201000011510 cancer Diseases 0.000 description 7
- 230000008961 swelling Effects 0.000 description 7
- NWXMGUDVXFXRIG-WESIUVDSSA-N (4s,4as,5as,6s,12ar)-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical compound C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]4(O)C(=O)C3=C(O)C2=C1O NWXMGUDVXFXRIG-WESIUVDSSA-N 0.000 description 6
- 229930195573 Amycin Natural products 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 238000002211 ultraviolet spectrum Methods 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical group CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 4
- 239000001768 carboxy methyl cellulose Substances 0.000 description 4
- 238000002189 fluorescence spectrum Methods 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- CWRATHCADZOYAT-UHFFFAOYSA-N methyl quinoline-3-carboxylate Chemical compound C1=CC=CC2=CC(C(=O)OC)=CN=C21 CWRATHCADZOYAT-UHFFFAOYSA-N 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 4
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- ARLVFKCLBYUINL-UHFFFAOYSA-N 9h-pyrido[3,4-b]indole-3-carboxylic acid Chemical compound N1C2=CC=CC=C2C2=C1C=NC(C(=O)O)=C2 ARLVFKCLBYUINL-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 3
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 3
- 230000005540 biological transmission Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical group CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- YGYLYUIRSJSFJS-QMMMGPOBSA-N benzyl (2s)-2-aminopropanoate Chemical compound C[C@H](N)C(=O)OCC1=CC=CC=C1 YGYLYUIRSJSFJS-QMMMGPOBSA-N 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 210000005069 ears Anatomy 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- GNPHAOQLHRZODS-ZQWQDMLBSA-N (1s,2s,3s,4s)-3,4-bis[butyl-[(4-phenoxyphenyl)methyl]carbamoyl]cyclobutane-1,2-dicarboxylic acid Chemical compound O=C([C@H]1[C@@H]([C@@H]([C@H]1C(O)=O)C(O)=O)C(=O)N(CCCC)CC=1C=CC(OC=2C=CC=CC=2)=CC=1)N(CCCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 GNPHAOQLHRZODS-ZQWQDMLBSA-N 0.000 description 1
- UUTKICFRNVKFRG-WDSKDSINSA-N (4R)-3-[oxo-[(2S)-5-oxo-2-pyrrolidinyl]methyl]-4-thiazolidinecarboxylic acid Chemical compound OC(=O)[C@@H]1CSCN1C(=O)[C@H]1NC(=O)CC1 UUTKICFRNVKFRG-WDSKDSINSA-N 0.000 description 1
- ADFXKUOMJKEIND-UHFFFAOYSA-N 1,3-dicyclohexylurea Chemical compound C1CCCCC1NC(=O)NC1CCCCC1 ADFXKUOMJKEIND-UHFFFAOYSA-N 0.000 description 1
- 240000006409 Acacia auriculiformis Species 0.000 description 1
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 1
- 206010061819 Disease recurrence Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 101000573199 Homo sapiens Protein PML Proteins 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- TZYWCYJVHRLUCT-VABKMULXSA-N N-benzyloxycarbonyl-L-leucyl-L-leucyl-L-leucinal Chemical compound CC(C)C[C@@H](C=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)OCC1=CC=CC=C1 TZYWCYJVHRLUCT-VABKMULXSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 239000007832 Na2SO4 Substances 0.000 description 1
- 240000002853 Nelumbo nucifera Species 0.000 description 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 1
- AKQOBHZKBDHWQI-BZEFIUHZSA-N O[C@H]1C[C@@H](CCC1)N1C(C2(C3=C1N=C(N=C3)NC1=CC=C(C=C1)S(=O)(=O)NC([2H])([2H])[2H])CC2)=O Chemical compound O[C@H]1C[C@@H](CCC1)N1C(C2(C3=C1N=C(N=C3)NC1=CC=C(C=C1)S(=O)(=O)NC([2H])([2H])[2H])CC2)=O AKQOBHZKBDHWQI-BZEFIUHZSA-N 0.000 description 1
- 208000032825 Ring chromosome 2 syndrome Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 201000009310 astigmatism Diseases 0.000 description 1
- TYQYRKDGHAPZRF-INIZCTEOSA-N benzyl (2s)-2-amino-3-(1h-indol-3-yl)propanoate Chemical compound O=C([C@H](CC=1C2=CC=CC=C2NC=1)N)OCC1=CC=CC=C1 TYQYRKDGHAPZRF-INIZCTEOSA-N 0.000 description 1
- YIRBOOICRQFSOK-NSHDSACASA-N benzyl (2s)-2-amino-3-methylbutanoate Chemical compound CC(C)[C@H](N)C(=O)OCC1=CC=CC=C1 YIRBOOICRQFSOK-NSHDSACASA-N 0.000 description 1
- MBRRYUQWSOODEO-LBPRGKRZSA-N benzyl (2s)-2-amino-4-methylpentanoate Chemical compound CC(C)C[C@H](N)C(=O)OCC1=CC=CC=C1 MBRRYUQWSOODEO-LBPRGKRZSA-N 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000012295 chemical reaction liquid Substances 0.000 description 1
- 238000002983 circular dichroism Methods 0.000 description 1
- 238000001142 circular dichroism spectrum Methods 0.000 description 1
- 229940127108 compound 5g Drugs 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 229960000935 dehydrated alcohol Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003194 forelimb Anatomy 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 102000054896 human PML Human genes 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229910000343 potassium bisulfate Inorganic materials 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M sodium bicarbonate Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y30/00—Nanotechnology for materials or surface science, e.g. nanocomposites
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nanotechnology (AREA)
- Organic Chemistry (AREA)
- Crystallography & Structural Chemistry (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Physics & Mathematics (AREA)
- Composite Materials (AREA)
- Condensed Matter Physics & Semiconductors (AREA)
- General Physics & Mathematics (AREA)
- Materials Engineering (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
本发明公开了通式I的14种1-(5,5-二甲基-1,3-二氧六环-2基甲基)-β-咔啉-3-甲酰氨基酸苄酯,公开了它们的制备方法,公开了它们的纳米结构、公开了它们对A549,HL60,S180,SW480和HT-29五株肿瘤细胞增殖的抑制活性,公开了它们对荷S180小鼠的肿瘤生长的抑制作用,公开了它们对小鼠的二甲苯炎症模型的抗炎作用。公开了它们与小牛胸腺DNA作用的光谱学特征;结果表明本发明的14种1-(5,5-二甲基-1,3-二氧六环-2基甲基)-β-咔啉-3-甲酰氨基酸苄酯具有优秀的抗肿瘤活性,因而具有作为抗肿瘤药物的临床应用前景。
Description
发明领域
本发明涉及通式I的14种1-(5,5-二甲基-1,3-二氧六环-2基甲基)-β-咔啉-3-甲酰氨基酸苄酯(式中AA为Gly,L-Ala,L-Asp,L-Glu,L-Phe,L-Ile,L-Lys,L-Leu,L-Met,L-Ser,L-Thr,L-Val,L-Trp,L-Tyr残基),涉及它们的制备方法,涉及它们的纳米结构,涉及它们对A549,HL60,S180,SW480和HT-29五株肿瘤细胞增殖的抑制活性,涉及它们对荷S180小鼠的肿瘤生长的抑制作用,进一步涉及它们对小鼠炎症的抑制作用。结果表明本发明的14种1-(5,5-二甲基-1,3-二氧六环-2基甲基)-β-咔啉-3-甲酰氨基酸苄酯具有优秀的抗肿瘤活性。本发明属于生物医药领域。
背景技术
癌症是当前世界严重影响人类健康、威胁人类生命的重要疾病之一。2012年,世界范围内的癌症新发病例为1670万例。而在我国,全国每分钟有6人被诊断为癌症,每年新发肿瘤病例约为312万例。因为炎症是公认的癌前病变,所以炎症既与癌症发病有关,也与癌症复发有关。抗炎可对抗癌产生贡献。
β-咔啉是天然来源生物碱,β-咔啉-3-羧酸具有抗肿瘤活性。根据炎症既与癌症发病及癌症复发的相关关系,发明人提出一种新思路。这种思路的创造性在于1)在β-咔啉-3-羧酸的1位引入抗炎活性药效团5,5-二甲基-1,3-二氧六环,在3位引入氨基酸苄酯可增强β-咔啉-3-羧酸的抗肿瘤活性;2)这样的分子不仅可进一步增强β-咔啉-3-羧酸的抗肿瘤活性,而且可具有抗炎活性;3)这样的分子可形成纳米结构,从而增强抗肿瘤和抗炎双重活性。按照这种思路的核心创造性,发明人提出本发明。
发明内容
本发明的第一个内容是提供14种新型1-(5,5-二甲基-1,3-二氧六环-2基甲基)-β-咔啉 -3-甲酰氨基酸苄酯。
本发明的第二个内容是提供制备14种新型1-(5,5-二甲基-1,3-二氧六环-2基甲基)-β-咔啉-3-甲酰氨基酸苄酯的方法,该方法包括以下步骤:
1)1,1,3,3-四甲氧基丙烷在稀盐酸催化下与2,2-二甲基-1,3-丙二醇反应生成2-(2,2-二甲氧基乙基)-5,5-二甲基-1,3-二氧六环(1);
2)2-(2,2-二甲氧基乙基)-5,5-二甲基-1,3-二氧六环(1)与色氨酸甲酯进行Pictet-Splenger缩合生成1-(5,5-二甲基-1,3-二氧六环-2-乙基)-1,2,3,4-四氢-β-咔啉-3-羧酸甲酯(2);
3)1-(5,5-二甲基-1,3-二氧六环-2基甲基)-1,2,3,4-四氢-β-咔啉-3-羧酸甲酯(2)被高锰酸钾氧化生成1-(5,5-二甲基-1,3-二氧六环-2基甲基)-β-咔啉-3-羧酸甲酯(3);
4)1-(5,5-二甲基-1,3-二氧六环-2基甲基)-β-咔啉-3-羧酸甲酯(3)水解生成1-(5,5-二甲基-1,3-二氧六环-2基甲基)-β-咔啉-3-羧酸(4);
5)1-(5,5-二甲基-1,3-二氧六环-2基甲基)-β-咔啉-3-羧酸(4)分别与14种氨基酸苄酯偶联得到14种新型1-(5,5-二甲基-1,3-二氧六环-2基甲基)-β-咔啉-3-甲酰氨基酸苄酯。
这些步骤可用图1概括。
本发明的第三个内容是用MTT法评价14种新型1-(5,5-二甲基-1,3-二氧六环-2基甲基)-β-咔啉-3-甲酰氨基酸苄酯抑制A549,HL60,S180,SW480,HT-29五株肿瘤细胞增殖的活性。
本发明的第四个内容是评价14种新型1-(5,5-二甲基-1,3-二氧六环-2基甲基)-β-咔啉-3-甲酰氨基酸苄酯抑制荷S180小鼠肿瘤生长的活性,并观察其对免疫指标的影响。
本发明的第五个内容是评价以5g,j,k,l为代表的新型1-(5,5-二甲基-1,3-二氧六环-2基甲基)-β-咔啉-3-甲酰氨基酸苄酯的抗炎活性。
本发明的第六个内容是是测定以5l为代表的新型1-(5,5-二甲基-1,3-二氧六环-2基甲基)-β-咔啉-3-甲酰氨基酸苄酯与CT-DNA作用的光谱学变化特征(包括紫外光谱、荧光光谱、CD谱图)。
本发明的第七个内容测定14种新型1-(5,5-二甲基-1,3-二氧六环-2基甲基)-β-咔啉-3-甲酰氨基酸苄酯的纳米结构。
附图说明
图1 1-(5,5-二甲基-1,3-二氧六环-2基甲基)-β-咔啉-3-甲酰氨基酸苄酯的合成路线.i)HCl,CH2Cl2;ii)TFA,CH2Cl2;iii)KMnO4,(CH3)2O;iv)NaOH,CH3OH;v)HOBt,DCC,NMM,THF,DMF.5a中AA为Gly残基,5b中AA为L-Ala残基,5c中AA为L-Asp残基,5d中AA为L-Glu残基,5e中AA为L-Phe残基,5f中AA为L-Ile残基,5g中AA为L-Lys残基,5h中AA为L-Leu残基,5i中AA为L-Met残基,5j中AA为L-Ser残基,5k中AA为L-Thr残基,5l中AA为L-Val残基,5m中AA为L-Trp残基,5n中AA为L-Tyr残基。
图2 5l与CT-DNA作用的紫外光谱变化。
图3 5l与CT-DNA作用的荧光光谱变化。
图4 5l与CT-DNA作用的CD谱图变化。
图5 5a-n在1×10-8mol/mL浓度下的透射电镜照片。
具体实施方式
为了进一步阐述本发明,下面给出一系列实施例。这些实施例完全是例证性的,它们仅用来对本发明进行具体描述,不应当理解为对本发明的限制。
实施例1制备2-(2,2-二甲氧基乙基)-5,5-二甲基-1,3-二氧六环(1)
向400mL二氯甲烷中加入32.8g(0.2mol)1,1,3,3-四甲氧基丙烷,室温搅拌下,逐滴加入0.8mL浓盐酸,待搅拌均匀后,加入6.24g(0.05mol)2,2-二甲基-1,3-丙二醇,反应24h后补加6.24g(0.05mol)2,2-二甲基-1,3-丙二醇,继续反应24h后停止反应。加入Na2CO3搅拌10min后静置30min。过滤除去Na2CO3固体干燥,减压浓缩除去二氯甲烷,然后在70℃温水浴下用水泵抽除未反应的1,1,3,3-四甲氧基丙烷,剩余液体置于冰浴条件下,过滤得18g(73%)标题化合物,为无色液体。ESI-MS(m/e):205[M+H]+.1H-NMR(300MHz,CDCl3):δ/ppm=4.54(t,1H),4.49(t,1H),3.57(d,2H),3.41(d,2H),3.36(s,6H),1.93-2.01(m,2H),1.21(s,3H),0.74(s,3H)。
实施2制备3S-1-(5,5-二甲基-1,3-二氧六环-2基甲基)-1,2,3,4-四氢-β-咔啉-3-羧酸甲酯(2)
向100mL二氯甲烷中依次加5.07g(20mmol)L-色氨酸甲酯盐酸盐和4.48g(22mmol)2-(2,2-二甲氧基乙基)-5,5-二甲基-1,3-二氧六环,然后缓慢加入5mL三氟乙酸,室温搅拌72h。加入2M NaOH调pH值至8,分离得到的有机层经无水硫酸钠干燥,过滤,滤液减压浓缩至干,残余物用硅胶柱层析纯化(二氯甲烷∶甲醇=80∶1),得0.78g(16%)标题物,为黄色固体,Rf=0.25(氯仿∶甲醇=25∶1)。ESI+-MS(m/e):359[M+H]+。
实施例3制备1-(5,5-二甲基-1,3-二氧六环-2基甲基)-β-咔啉-3-羧酸甲酯(3)
将1.79g(5mmol)3S-1-(5,5-二甲基-1,3-二氧六环-2基甲基)-1,2,3,4-四氢-β-咔啉-3-羧酸甲酯溶于100mL丙酮,加1.58g(10mmol)高锰酸钾,室温反应24h,TLC监测原料点消失。反应物过滤,滤液减压浓缩浓缩,得1.44g(81%)标题化合物,为黄色固体。Rf=0.25(氯仿∶甲醇=25∶1)。ESI+-MS(m/e):355[M+H]+;1H-NMR(300MHz,CDCl3):δ/ppm=9.78(s,1H),8.82(s,1H),8.18(d,J=7.8Hz,1H),7.58(m,2H),7.35(m,1H),4.94(t,J=4.5Hz,1H),4.05(s,3H),3.46-3.48(m,2H),3.64-3.74(m,4H),1.17(s,3H),0.72(s,3H)。
实施例4制备1-(5,5-二甲基-1,3-二氧六环-2基甲基)-β-咔啉-3-羧酸(4)
向40ml甲醇中加1.44g(4mmol)1-(5,5-二甲基-1,3-二氧六环-2基甲基)-β-咔啉-3-羧酸甲酯,冰盐浴搅拌下缓慢滴入2M氢氧化钠溶液调pH至12,TLC监测原料点消失。反应液调pH至中性并减压浓缩至干,残留物用二氯甲烷溶解,将不溶物滤除,滤液减压浓缩至干,得1.27g(92%)标题化合物,为黄色固体。ESI-MS(m/e):339[M-H]-;1H-NMR(300MHz,CDCl3):δ/ppm=12.08(s,1H),8.79(s,1H),8.36(d,J=7.8Hz,1H),7.63(m,2H),7.32(m,1H),5.14(t,J=5.4Hz,1H),3.61(m,6H),1.15(s,3H),0.69(s,3H)。
实施例5制备1-(5,5-二甲基-1,3-二氧六环-2基甲基)-β-咔啉-3-甲酰甘氨酸苄酯(5a)
冰浴下向500mg(1.47mmol)1-(5,5-二甲基-1,3-二氧六环-2基甲基)-β-咔啉-3-羧酸中依次加入2mL DMF和20mL四氢呋喃,229mg(1.7mmol)1-羟基苯并三唑(HOBt)及343mg(1.7mmol)二环己基碳二亚胺(DCC),活化30min得到活化液。384mg(1.7mmol)HCl·Gly-OBzl于5mL四氢呋喃,用N-甲基吗啉(NMM)调pH至中性并加到前面的活化液中,再用NMM调pH至8,室温反应8h后减压浓缩至干。残留物加50mL乙酸乙酯溶解,滤除不溶的二环己基脲(DCU),滤液依次用饱和NaHCO3溶液(20mL×3),饱和NaCl溶液(20mL×3),5%KHSO4溶液,饱和NaCl溶液(20mL×3),5%NaHCO3溶液(20mL×3),饱和NaCl溶液(20mL×3)各洗3遍,合并的乙酸乙酯层用无水Na2SO4干燥,过滤,滤液减压浓缩至干,得到的黄色油状物经硅胶柱层析纯化(二氯甲烷∶甲醇=80∶1),得208mg(28%)标题化合物,为无色粉末。ESI-MS(m/e):508[M+H]+;Mp:137-138℃; 1H-NMR(300MHz,CDCl3):δ/ppm=9.47(s,1H),8.84(s,1H),8.66(s,1H),8.20(d,J=7.8Hz,1H),7.58(m,2H),7.32-7.38(m,6H),5.27(s,2H),4.92(t,J=4.5Hz,1H),4.39(d,J=5.7Hz,2H),3.71(d,J=11.1Hz,2H),3.57(d,J=4.5Hz,2H),1.17(s,3H),3.51(d,J=11.1Hz,2H),0.75(s,3H).13C-NMR(75MHz,CDCl3):δ/ppm=170.51, 165.78,141.37,140.36,139.03,136.79,136.47,128.89,128.52,128.52,128.45,128.45,128.37,122.56,121.73,120.42,113.05,112.76,101.37,76.64,76.64,66.30,41.73,30.24,30.24,23.34,21.88,19.01。
实施例6制备1-(5,5-二甲基-1,3-二氧六环-2基甲基)-β-咔啉-3-甲酰丙氨酸苄酯(5b)
按照实施例5的方法,从500mg(1.47mmol)1-(5,5-二甲基-1,3-二氧六环-2基甲基)-β-咔啉-3-羧酸和366mg(1.7mmol)HCl·Ala-OBzl得到228mg(31%)标题化合物,为无色粉末。ESI-MS(m/e):502[M+H]+;Mp:115-117℃; 1H-NMR(300MHz,CDCl3):δ/ppm=11.90(s,1H),8.81(d,J=7.5Hz,1H),8.70(s,1H),8.35(d,J=7.8Hz,1H),7.62(m,2H),7.35(m,6H),5.18(m,3H),4.68(t,J=4.5Hz,1H),3.47-3.55(m,6H),1.52(d,J=7.2Hz,3H),1.16(s,3H),0.67(s,3H).13C-NMR(75MHz,CDCl3):δ/ppm=173.09,165.21,140.69,139.21,139.16,137.26,135.64,129.40,128.86,128.61,128.52,128.31,128.08,122.37,122.15,120.58,113.67,111.89,101.85,77.42,77.29,66.99,48.29,42.21,30.93,22.70,21.79,14.13。
实施例7制备1-(5,5-二甲基-1,3-二氧六环-2基甲基)-β-咔啉-3-甲酰天冬氨酸双苄酯(5c)
按照实施例5的方法,从500mg(1.47mmol)1-(5,5-二甲基-1,3-二氧六环-2基甲基)-β-咔啉-3-羧酸和441mg(1.7mmol)HCl·Asp(OBzl)-OBzl得304mg(33%)标题化合物,为无色粉末。ESI+-MS(m/e):636[M+H]+;Mp:85-86℃; 1H-NMR(300MHz,CDCl3):δ/ppm=11.90(s,1H),9.14(d,J=8.4Hz,1H),8.73(s,1H),8.37(d,J=7.8Hz,1H),7.63(m,2H),7.31(m,12H),5.05-5.18(m,6H),3.35-3.55(m,6H),3.18-3.21(m,2H),1.15(s,3H),0.65(s,3H).13C-NMR(75MHz,CDCl3):δ/ppm=171.12,170.99,165.16,141.36,140.33,138.65,136.83,136.25,128.95,128.82,128.82,128.82,128.82,128.47,128.47,128.31,128.31,128.31,128.31,127.07,126.86,122.62,121.73,120.49,113.27,112.77,101.32,76.70,76.70,66.82,66.34,49.25,39.17,36.48,30.2,23.32,21.87。
实施例8制备1-(5,5-二甲基-1,3-二氧六环-2基甲基)-β-咔啉-3-甲酰谷氨酸双苄酯(5d)
按照实施例5的方法,从500mg(1.47mmol)1-(5,5-二甲基-1,3-二氧六环-2基甲基)-β-咔啉-3-羧酸和465mg(1.7mmol)HCl·Glu(OBzl)-OBzl得226mg(24%)标题化合物,为无色粉末。ESI-MS(m/e):650[M+H]+;Mp:56-57℃; 1H-NMR(300MHz,CDCl3):δ/ppm=9.51(s,1H),8.81(s,1H),8.72(d,J=7.8Hz,1H),8.19(d,J=8.1Hz,1H),7.58(m,2H),7.35(m,6H),5.24(s,2H),5.08(s,2H),5.01(m,1H),4.92(t,J=4.5Hz,J=4.5Hz,1H),3.73-3.67(m,2H),3.58(d,J=4.5Hz,2H),3.51(d,J=11.1Hz,2H),2.52(m,2H),2.25(m,2H),1.19(s,3H),0.75(s,3H).13C-NMR(75MHz,CDCl3):δ/ppm=172.54,171.83,165.47,140.71,140.73,139.18,137.27,135.82,135.42,129.42,128.60,128.60,128.56,128.56,128.48,128.48,1128.36,128.36,128.18,128.18,128.18,128.18,127.64,126.97,122.32,122.13,120.62,113.80,111.90,101.77,77.01,67.19,66.40,65.39,51.82,30.56,30.11,27.95,27.95,23.07,21.75。
实施例9制备1-(5,5-二甲基-1,3-二氧六环-2基甲基)-β-咔啉-3-甲酰苯丙氨酸苄酯(5e)
按照实施例5的方法,从500mg(1.47mmol)1-(5,5-二甲基-1,3-二氧六环-2基甲基)-β-咔啉-3-羧酸和496mg(1.7mmol)HCl·Phe-OBzl得213mg(25%)标题化合物,为无色粉末。ESI-MS(m/e):578[M+H]+;Mp:75-76℃; 1H-NMR(300MHz,CDCl3):δ/ppm=9.43(s,1H),8.80(s,1H),8.68(d,J=8.4Hz,1H),8.18(d,J=7.8Hz,1H),7.58(m,2H),7.39(m,12H),5.20(m,3H),4.88(t,J=4.5Hz,1H),3.71(d,J=11.1Hz,2H),3.46-3.56(m,4H),3.30(d,J=6.3Hz,2H),1.22(s,3H),0.76(s,3H).13C-NMR(75MHz,CDCl3):δ/ppm=171.3,165.18,140.66,139.12,137.26,136.18,135.38,129.47,129.47,129.47,129.39,128.53,128.49,128.49,128.49,128.49,128.41,128.31,122.37,122.11,120.59,113.59,111.86,101.86,101.86,77.20,74.35,67.00,66.40,65.39,51.82,53.48,42.13,38.54,30.13,21.93,21.78。
实施例10制备1-(5,5-二甲基-1,3-二氧六环-2基甲基)-β-咔啉-3-甲酰异亮氨酸苄酯(5f)
按照实施例5的方法,从500mg(1.47mmol)1-(5,5-二甲基-1,3-二氧六环-2-乙基)-β-咔啉-3-羧酸和438mg(1.7mmol)HCl·Ile-OBzl得205mg(26%)标题化合物,为无色粉末。ESI-MS(m/e):544[M+H]+;Mp:98-99℃; 1H-NMR(300MHz,CDCl3):δ/ppm=9.48(s,1H),8.82(s,1H),8.70(d,J=9Hz,1H),8.18(d,J=7.8Hz,1H),7.58(m,2H),7.37(m,6H),5.24(q,J=12.3Hz,2H),4.93(m,2H),3.72(d,J=11.1Hz,2H),3.58(d,J=4.5Hz,4H),3.52(d,J=9.6Hz,2H),2.09(m,1H),1.58(m,1H),1.37(m,1H),1.23(s,3H),1.03(d,J=6.9Hz,3H),0.96(t,J=7.2Hz,J3H),0.766(s,3H).13C-NMR(75MHz,CDCl3):δ/ppm=172.06,165.39,140.68,139.27,139.07,137.23,135.63,129.42,128.60,128.54,128.49, 128.41,128.26,122.37,122.12,120.56,113.70,111.87,101.86,77.22,66.79,56.78,42.26,38.31,30.15,29.28,28.27,25.25,23.11,21.79,15.71,11.59。
实施例11制备1-(5,5-二甲基-1,3-二氧六环-2基甲基)-β-咔啉-3-甲酰赖氨酸苄酯(5g)
按照实施例5的方法,从500mg(1.47mmol)1-(5,5-二甲基-1,3-二氧六环-2基甲基)-β-咔啉-3-羧酸和463mg(1.7mmol)HCl·Lys(Boc)-OBzl得80mg(10%)标题化合物,为无色粉末。ESI-MS(m/e):559[M+H]+;Mp:122-123℃; 1H-NMR(300MHz,CDCl3):δ/ppm=1.97(s,1H),8.787(d,J=7.8Hz,1H),8.710(s,1H),8.35(d,J=8.4Hz,1H),7.78(s,2H)7.61(m,2H),7.33(m,6H),5.21(m,3H),4.65-4.68(m,1H),3.23-3.63(m,6H),2.75-2.77(m,2H),1.95-1.97(m,2H),1.59(m,2H),1.39(m,2H),1.16(s,3H),0.67(s,3H).13C-NMR(75MHz,CDCl3):δ/ppm=172.35,165.37,158.17,141.4,140.36,138.78,136.85,136.41,128.89,128.53,128.53,128.46,128.26,128.26,122.53,121.69,120.48,113.14,112.81,101.82,101.3276.71,76.71,66.59,52.48,39.47,39.13,31.21,30.21,27.05,23.23,22.81,22.50。
实施例12制备1-(5,5-二甲基-1,3-二氧六环-2基甲基)-β-咔啉-3-甲酰亮氨酸苄酯(5h)
按照实施例5的方法,从500mg(1.47mmol)1-(5,5-二甲基-1,3-二氧六环-2基甲基)-β-咔啉-3-羧酸和438mg(1.7mmol)HCl·Leu-OBzl得295mg(37%)标题化合物,为无色粉末。ESI-MS(m/e):544[M+H]+;Mp:72-73℃; 1H-NMR(300MHz,CDCl3):δ/ppm=9.67(s,1H),8.73(s,1H),8.59(d,J=8.4Hz,1H),8.10(d,J=7.8Hz,1H),7.53(m,2H),7.33(m,6H),5.28(s,2H),5.00(m,2H),3.67-3.71(m,2H),3.58(d,J=4.5Hz,2H),3.51(d,J=11.8Hz,2H),1.82(m,3H),1.20(s,3H),1.03(t,J=6.0Hz,J=6.0Hz,6H),0.73(s,3H). 13C-NMR(75MHz,CDCl3):δ/ppm=173.14,165.44,140.70,139.10,137.18,135.67,129.34,128.56,128.48,128.48,128.25,128.12,128.12,122.30,122.03,120.51,113.62,111.93,101.83,77.51,77.39,66.90,53.05,51.05,42.00,36.23,30.13,25.00,23.08,22.96,22.04,21.77。
实施例13制备1-(5,5-二甲基-1,3-二氧六环-2基甲基)-β-咔啉-3-甲酰-L-蛋氨酸苄酯(5i)
按照实施例5的方法,从500mg(1.47mmol)1-(5,5-二甲基-1,3-二氧六环-2基甲基)-β-咔啉-3-羧酸和468mg(1.7mmol)HCl·Met-OBzl得140mg(17%)标题化合物,为无色粉 末。ESI-MS(m/e):562[M+H]+;Mp:78-79℃; 1H-NMR(300MHz,CDCl3):δ/ppm=9.54(s,1H),8.83(s,1H),8.80(s,1H),8.19(d,J=7.8Hz,1H),7.58(m,2H),7.38(m,6H),5.28(q,J=12.3Hz,2H),5.05(m,1H),4.95(t,J=9Hz,1H),3.70-3.74(m,2H),3.59(d,J=4.5Hz,2H),3.52(d,J=3Hz,1H),3.52(d,J=1Hz,1H),3.24(m,1H),3.13(m,1H),2.89(s,3H),2.67(m,1H),2.41(m,1H),1.19(s,3H),0.76(s,3H).13C-NMR(75MHz,CDCl3):δ/ppm=170.87,165.80,140.69,139.42,135.04,135.04,129.37,128.75,128.75,128.67,128.43,128.43,122.26,122.10,120.71,113.84,111.94,101.80,101.72,77.20,77.20,67.70,53.03,51.35,50.95,40.82,30.14,26.05,23.08,21.76。
实施例14制备1-(5,5-二甲基-1,3-二氧六环-2基甲基)-β-咔啉-3-甲酰丝氨酸苄酯(5j)
按照实施例5的方法,从500mg(1.47mmol)1-(5,5-二甲基-1,3-二氧六环-2基甲基)-β-咔啉-3-羧酸和394mg(1.7mmol)HCl·Ser-OBzl得86mg(11%)标题化合物,为无色粉末。ESI-MS(m/e):518[M+H]+;Mp:90-91℃; 1H-NMR(300MHz,CDCl3):δ/ppm=9.52(s,1H),9.03(d,J=7.5Hz,1H),8.82(s,1H),8.18(d,J=7.8Hz,1H),7.59(m,2H),7.37(m,6H),5.31(s,2H),4.99(m,1H),4.93(t,J=9Hz,1H),4.16(m,2H),3.71(d,J=7.5Hz,11.1H),3.57(d,J=4.5Hz,2H),3.51(d,J=11.1Hz,2H),3.00(s,1H),1.18(s,3H),0.740(s,3H).13C-NMR(75MHz,CDCl3):δ/ppm=170.37,165.39,140.72,139.30,137.31,135.34,135.34,129.41,128.64,128.64,128.42,128.10,128.10,122.30,122.13,120.67,113.86,111.90,101.73,101.73,77.19,77.19,67.40,64.13,55.59,42.08,30.11,23.505,21.74。
实施例15制备1-(5,5-二甲基-1,3-二氧六环-2基甲基)-β-咔啉-3-甲酰苏氨酸苄酯(5k)
按照实施例5的方法,从500mg(1.47mmol)1-(5,5-二甲基-1,3-二氧六环-2基甲基)-β-咔啉-3-羧酸和417mg(1.7mmol)HCl·Thr-OBzl得300mg(38%)标题化合物,为无色粉末。ESI-MS(m/e):532[M+H]+;Mp:133-134℃; 1H-NMR(300MHz,CDCl3):δ/ppm=9.66(s,1H),8.96(d,J=7.5Hz,1H),8.76(s,1H),8.10(d,J=7.8Hz,1H),7.55(m,2H),7.33(m,6H),4.94(q,J=27Hz,2H),4.94(m,2H),4.53(m,1H),3.68(d,J=7.5Hz,11.1H),3.53(d,J=4.5Hz,2H),3.48(d,J=11.1Hz,2H),3.33(s,1H),2.08(s,1H),1.35(d,J=6.3Hz,3H),0.74(s,3H),1.28(s,3H),0.74(s,3H). 13C-NMR(75MHz,CDCl3):δ/ppm=170.99,165.63,140.70,139.26,137.33,135.45,135.45, 129.40,128.60,128.60,128.35,128.12,128.12,122.34,122.12,120.62,113.90,111.89,101.80,101.80,77.19,77.19,68.77,67.21,57.97,42.13,30.12,23.09,21.76,20.07。
实施例16制备1-(5,5-二甲基-1,3-二氧六环-2基甲基)-β-咔啉-3-甲酰缬氨酸苄酯(5l)
按照实施例5的方法,从500mg(1.47mmol)1-(5,5-二甲基-1,3-二氧六环-2基甲基)-β-咔啉-3-羧酸和414mg(1.7mmol)Val-OBzl得112mg(14%)标题化合物,为无色粉末。ESI-MS(m/e):530[M+H]+;Mp:99-101℃; 1H-NMR(300MHz,CDCl3):δ/ppm=9.60(s,1H),8.78(s,1H),8.74(d,J=9.1Hz,1H),8.14(d,J=8.1Hz,1H),7.55(m,2H),7.36(m,6H),5.25(q,J=34.2Hz,2H),4.96(t,J=9Hz,1H),4.90(t,J=14.4Hz,1H),3.75(d,J=11.1Hz,2H),3.59(d,J=4.5Hz,2H),3.48(d,J=11.1Hz,2H),2.40(m,1H),1.28(s,3H),1.06(t,J=12.9Hz,1H),0.750(s,3H).13C-NMR(75MHz,CDCl3):δ/ppm=172.09,165.57,140.71,139.16,139.09,127.20,135.64,135.64,129.35,128.66,128.56,128.47,128.21,128.18,122.32,122.03,120.50,113.60,111.92,101.83,101.83,77.32,77.29,66.84,53.04,42.02,31.72,30.12,23.10,21.78,19.26,18.04。
实施例17制备1-(5,5-二甲基-1,3-二氧六环-2基甲基)-β-咔啉-3-甲酰色氨酸苄酯(5m)
按照实施例5的方法,从500mg(1.47mmol)1-(5,5-二甲基-1,3-二氧六环-2基甲基)-β-咔啉-3-羧酸和562mg(1.7mmol)HCl·Trp-OBzl得300mg(33%)标题化合物,为无色粉末。ESI-MS(m/e):617[M+H]+;Mp:99-100℃; 1H-NMR(300MHz,CDCl3):δ/ppm=9.39(s,1H),8.82(s,1H),8.75(d,J=7.4Hz,1H),8.19(d,J=8.1Hz,1H),7.98(s,1H),7.67(d,J=7.8Hz,1H),7.57(m,2H),7.32(m,6H),7.22(t,J=15.3Hz,1H),7.08(t,J=15.0Hz,1H),6.96(d,J=2.1Hz,1H),5.29(m,1H),5.14(s,2H),4.81(t,J=9.3Hz,1H),3.70(d,J=11.1Hz,2H),3.41-3.54(m,6H)1.22(s,3H),0.76(s,3H).13C-NMR(75MHz,CDCl3):δ/ppm=171.75,165.39,155.53,140.74,139.01,138.85,137.20,135.38,130.55,129.33,128.52,128.52,128.41,128.41,128.30,128.30,127.27,122.24,122.04,120.51,115.54,113.47,111.88,101.91,101.91,77.37,77.22,67.01,58.35,41.57,37.55,30.10,23.03,21.69。
实施例18制备1-(5,5-二甲基-1,3-二氧六环-2基甲基)-β-咔啉-3-甲酰酪氨酸苄酯(5n)
按照实施例5的方法,从500mg(1.47mmol)1-(5,5-二甲基-1,3-二氧六环-2基甲基)-β- 咔啉-3-羧酸和523mg(1.7mmol)HCl·Tyr-OBzl得90mg(10%)标题化合物,为无色粉末。ESI-MS(m/e):594[M+H]+;Mp:115-116℃; 1H-NMR(300MHz,CDCl3):δ/ppm=9.43(s,1H),8.769(s,1H),8.68(d,J=8.4Hz,1H),8.16(d,J=7.8Hz,1H),7.55(m,2H),7.37(m,6H),7.02(d,J=7.8Hz,2H),6.713(d,J=8.4Hz,2H),5.15(m,3H),4.88(t,J=4.5Hz,J=4.5Hz,1H),3.72(d,J=11.1Hz,2H),3.50-3.53(m,4H),3.22(d,J=6Hz,2H),1.27(s,3H),0.74(s,3H).13C-NMR(75MHz,CDCl3):δ/ppm=171.75,165.39,155.53,140.74,139.01,138.85,137.20,135.38,130.55,129.33,128.52,128.52,128.41,128.41,128.30,128.30,127.27,122.24,122.04,120.51,115.54,113.47,111.88,101.91,101.91,77.37,77.22,67.01,58.35,41.57,37.55,30.10,23.03,21.69。
实验例1评价5a-n抗肿瘤细胞增殖的活性
5a-n均用含1%DMSO的PBS配制成所需浓度。肿瘤细胞株包括A549(人非小细胞肺癌细胞);HT-29(人结肠癌细胞);HL60(人早幼粒细胞白血病细胞);S180(鼠肉瘤细胞);SW480(人结肠癌细胞)。A549和S180细胞选用DMEM培养基,其他细胞选用RPMI-1640培养基。培养液中含10%灭火的胎牛血清和1×105U·L-1青霉素和100mg·L-1链霉素。
将生长状态良好,处于对数生长期的A549,SW480,HT-29细胞按5×104个/mL的密度接种于96孔板,每孔100μL。置于37℃,5%CO2培养箱中培养4小时待贴壁。细胞按预设的浓度梯度100μM,50μM,25μM,12.5μM和6.25μM加入经灭菌处理的5a-n溶液,每孔25μL,对照孔加入等体积的RPMI-1640,平行5孔。在37℃的5%CO2培养箱中培养48小时,每孔加入25μL浓度为5mg/mL的MTT溶液,继续置于37℃的5%CO2培养箱中培养4小时。小心吸出上清液,每孔加入100μLDMSO溶解紫色残留物(甲瓒),平板振荡10分钟使沉淀全部溶解,于540nm酶标仪上测定OD值(吸光度),波长为540nm。按照抑制率=1-[(RPMI-1640组平均OD值-5a-n组平均OD值)/RPMI-1640组平均OD值]×100%计算抑制率。每个化合物重复3次,以抑制率对5a-n浓度作图,求出IC50值。
将生长状态良好,处于对数生长期的S180(半贴壁细胞),HL60细胞按照4×104个/mL的密度接种于96孔板,每孔100μL。细胞按预设的浓度梯度100μM,50μM,25μM,12.5μM和6.25μM加入经灭菌处理的5a-n,每孔25μL,对照孔加入等体积的RPMI-1640,平行5孔。在37℃的5%CO2培养箱中培养48小时,每孔加入25μL浓度为5mg/mL的MTT溶液,继续置于37℃的5%CO2培养箱中培养4小时。离心3分钟(3000rpm/min)。 小心吸出上清液,每孔加入100μLDMSO溶解紫色残留物(甲瓒),平板振荡10分钟使沉淀全部溶解,于540nm酶标仪上测定OD值(吸光度),波长540nm。按照抑制率=1-[(RPMI-1640组平均OD值-5a-n组平均OD值)/RPMI-1640组平均OD值]×100%计算抑制率。每个化合物重复3次,以抑制率对5a-n浓度作图,求出IC50值。
结果见表1。数据表明除5k外所有化合物抑制5株肿瘤细胞增殖的IC50都超过100μM。可见,5a-n没有细胞毒作用。
表1 5a-n抗肿瘤细胞增殖的活性(IC50,μM)
实验例2评价5a-n抑制肿瘤生长的活性
测定前将本发明的化合物5a-n用0.5%羧甲基纤维素钠配制成浓度为1μmol/kg混悬液。阳性对照阿霉素配制成2μmol/kg生理盐水溶液。ICR雄性小鼠(清洁级,体重20+2g)随机分组,每组12只小鼠。无菌条件下取接种于ICR小鼠7-10天的S180肉瘤,加入适量生理盐水配制成瘤细胞悬液,细胞数为2×107/mL,接种于健康雄性ICR小鼠前肢腋皮下,每只小鼠注射0.2mL。肿瘤接种24h后,治疗组小鼠每日1次口服5a-n的水溶 液,剂量为1μmol/kg,连续7天。空白组小鼠每日1次口服0.5%羧甲基纤维素钠水溶液,剂量为0.2mL/20g,连续7天。阳性对照组小鼠每日1次腹腔注射阿霉素,剂量为2μmol/kg,连续7天。第8天,称小鼠体重,并剖取各组小鼠的肿瘤称重,最后统计各组动物的抑瘤率。实体瘤的疗效以瘤重及抑制百分率表示,瘤重抑制率%=(1-给药组瘤重/空白组瘤重)×100%。数据列入表2。
实验观察到,本发明的化合物在1μmol/kg剂量下都显示出不同程度的抗肿瘤活性,除5a,e,n外,其余化合物与空白组均有显著性差异,其中5g,j,l,m与阳性药阿霉素活性相当。
表2.3’,5a-n对S180荷瘤小鼠的瘤重的影响
注:n=12;3’、5a-n:剂量1μmol/kg,口服;阿霉素:剂量为2μmol/kg,静脉注射;a)与空白组比较p<0.01;b)与空白组比较p<0.01,与ADM组比较p>0.05,与3’比较p<0.01;c)与空白组比较p<0.01,与ADM组比较p>0.05,与3’比较p<0.05;d)与空白组比较p<0.01,与ADM组比较p>0.05,与3’比较p>0.05。
临床研究表明,多数抗肿瘤药物在杀伤肿瘤细胞的同时,会造成免疫系统损伤,因此脾指数作为衡量免疫指标的参数之一,是研究抗肿瘤药物毒性大小重要参考指标。本发明对化合物的脾指数影响进行分析,除化合物5b,l,n与空白组比较存在差异(p<0.05)外,其余化合物的脾指数与空白组比较均没有显著性差异(p<>0.05)。而阳性对照药阿霉素与空白组比较存在显著性差异(p<<0.01)。由此可见,本发明的化合物与阿霉素比较,毒性较小。
表3.3’,5a-n对S180荷瘤小鼠各脏器指标的影响结果
实验例3不同剂量的5j,l抑制肿瘤生长的活性
按照实验例2的方法,选取抗肿瘤活性好的5j,l考察4μmol/kg,1μmol/kg和0.25μmol/kg三个剂量下的抗肿瘤活性,结果见表3。数据表明化合物5j,l在体内随着剂量的减小,抗肿瘤活性也逐渐降低,说明5j,l的抗肿瘤作用是剂量依赖性的。
表4 5j,l对荷S180小鼠肿瘤重量影响的量效关系
注:a)与空白组比较p<0.01,与0.25μmol/kg剂量组比较p<0.05;b)与空白组比较p<0.01,与0.25μmol/kg剂量组比较p<0.01;
实验例4化合物5g,j,l,m体内抗炎活性评价
5g,j,l,m用0.5%羧甲基纤维素钠配制成混悬液,口服剂量为1μmol/kg。阳性对照阿司匹林用0.5%羧甲基纤维素钠配制成混悬液,口服剂量为200mg/kg。ICR雄性小鼠(清洁级,体重20+2g)随机分组,每组12只小鼠。使用前室温下适应1天。实验开始时,分组灌胃给药,给药30min后,往小鼠右耳前后均匀涂抹40μl二甲苯,1小时后将小鼠颈椎断颈处死,沿耳廓基线剪下两耳,在对称处用7mm的打孔器打孔,取左右耳片,分别称重。计算肿胀度和肿胀抑制率。抗炎疗效以肿胀度抑制率表示,计算如下:,肿胀度=右耳片重-左耳片重,肿胀抑制率%=(空白组肿胀度-给药组肿胀度)/空白组肿胀度×100%
表5 5g,j,l,m对小鼠耳廓肿胀度的影响
注:n=12,口服;阿司匹林剂量:200mg/kg;5g,j,l,m:1μmol/kg;a)与空白组比较p<0.01
实验例55l与DNA的作用机制研究
取1ml浓度为1.76×10-4mol/L的CT-DNA测定其紫外光谱;之后逐次加入20μL浓度为2.0×10-3mol/L的化合物5l溶液(体积变化忽略不计,DNA浓度认为保持恒定),每次待作用5min后再测定混合液的紫外光谱,考察CT-DNA与5l结合前后紫外光谱的变化。见图2。由图可以看出:DNA与5l作用以后的吸收峰增高产生增色效应,且峰形峰位发生了改变。紫外光谱的变化说明5l与DNA之间可能存在相互作用。
取1mL浓度为2×10-5mol/L的5l溶液测定其荧光光谱;之后逐次加入浓度为1.76×10-4mol/L的CT-DNA溶液(体积变化忽略不计,5l浓度认为保持恒定),每次待作用5min后再测定混合物的荧光光谱。见图3。(荧光发射和激发狭缝分别为5nm,5nm,固定激发波长271nm,扫描速度为1500nm/min。)由图可以看出,随着CT-DNA的加入,5l产生荧光猝灭,峰形和峰位基本保持不变。荧光光谱的变化也可以说明5l与DNA之间存在相互作用。
配制5l和DNA的混合液,其终浓度分别为2.0×10-4mol·L-1和1.76×10-4mol·L-1;配制浓度为1.76×10-4mol·L-1的CT-DNA液,于室温下,分别测定两种溶液的圆二色散光谱。见图4。由图可以看出,5l与DNA作用后,DNA的CD光谱正、负峰的摩尔椭圆度θ值减小,振幅减弱;且正峰红移;负峰蓝移。由此可以进一步推断5l与DNA之间存在相互作用。
实验例5测定5a-n的透射电镜照片
以无水乙醇为溶剂,将化合物5a-n配制成浓度为10-8(血药浓度值)mol/mL的溶液,用盐酸PBS溶液调pH至5.4,在透射电镜点样专用的铜网上点样,将点样后的铜网于37℃烘干,使用透射电镜(TEM,JEM-1230,JEOL)观察化合物的纳米形态。得到的照片见图5。结果表明,5a-n均可形成纳米球状结构,直径分布在20-300nm范围。
Claims (5)
1.通式I的14种1-(5,5-二甲基-1,3-二氧六环-2基甲基)-β-咔啉-3-甲酰氨基酸苄酯,式中AA为Gly,L-Ala,L-Asp,L-Glu,L-Phe,L-Ile,L-Lys,L-Leu,L-Met,L-Ser,L-Thr,L-Val,L-Trp,L-Tyr残基,
2.权利要求1的14种1-(5,5-二甲基-1,3-二氧六环-2基甲基)-β-咔啉-3-甲酰氨基酸苄酯的制备方法,该方法包括以下步骤:
1)1,1,3,3-四甲氧基丙烷在稀盐酸催化下与2,2-二甲基-1,3-丙二醇反应生成2-(2,2-二甲氧基乙基)-5,5-二甲基-1,3-二氧六环(1);
2)2-(2,2-二甲氧基乙基)-5,5-二甲基-1,3-二氧六环(1)与色氨酸甲酯进行Pictet-Splenger缩合生成3S-1-(5,5-二甲基-1,3-二氧六环-2基甲基)-1,2,3,4-四氢-β-咔啉-3-羧酸甲酯(2);
3)3S-1-(5,5-二甲基-1,3-二氧六环-2基甲基)-1,2,3,4-四氢-β-咔啉-3-羧酸甲酯(2)被高锰酸钾氧化生成1-(5,5-二甲基-1,3-二氧六环-2基甲基)-β-咔啉-3-羧酸甲酯(3);
4)1-(5,5-二甲基-1,3-二氧六环-2基甲基)-β-咔啉-3-羧酸甲酯(3)水解生成1-(5,5-二甲基-1,3-二氧六环-2基甲基)-β-咔啉-3-羧酸(4);
5)1-(5,5-二甲基-1,3-二氧六环-2基甲基)-β-咔啉-3-羧酸(4)分别与14种氨基酸苄酯偶联得到14种1-(5,5-二甲基-1,3-二氧六环-2基甲基)-β-咔啉-3-甲酰氨基酸苄酯。
3.权利要求1的14种1-(5,5-二甲基-1,3-二氧六环-2基甲基)-β-咔啉-3-甲酰氨基酸苄酯在制备对A549,HL60,S180,SW480和HT-29五株肿瘤细胞抑制药物中的应用。
4.权利要求1的14种1-(5,5-二甲基-1,3-二氧六环-2基甲基)-β-卡啉-3-甲酰氨基酸苄酯在制备抗炎药物中的应用。
5.权利要求1的14种1-(5,5-二甲基-1,3-二氧六环-2基甲基)-β-咔啉-3-甲酰氨基酸苄酯在制备抗肿瘤药物中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310225687.4A CN104211700B (zh) | 2013-06-05 | 2013-06-05 | 咔啉羧酸类似物,其合成,纳米结构,抗肿瘤活性和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310225687.4A CN104211700B (zh) | 2013-06-05 | 2013-06-05 | 咔啉羧酸类似物,其合成,纳米结构,抗肿瘤活性和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104211700A CN104211700A (zh) | 2014-12-17 |
CN104211700B true CN104211700B (zh) | 2016-08-10 |
Family
ID=52093645
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310225687.4A Expired - Fee Related CN104211700B (zh) | 2013-06-05 | 2013-06-05 | 咔啉羧酸类似物,其合成,纳米结构,抗肿瘤活性和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104211700B (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106349244B (zh) * | 2015-07-13 | 2018-07-27 | 首都医科大学 | 苯并咪唑并喹唑啉二甲氧苯氧乙酰-AA-OBzl,其合成,活性和应用 |
CN112979751B (zh) * | 2019-12-02 | 2022-04-22 | 首都医科大学 | 二氧六环修饰的四氢咔啉-3-甲酰-The-HGK、其制备、抗炎活性和应用 |
CN112898377B (zh) * | 2019-12-02 | 2022-04-22 | 首都医科大学 | 二氧六环修饰的四氢咔啉-3-甲酰-The-HGE、其制备、抗炎活性和应用 |
CN111718380B (zh) * | 2020-07-30 | 2022-05-06 | 首都医科大学 | 咔啉钌类络合物及其制备方法和应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1743327A (zh) * | 2004-09-03 | 2006-03-08 | 首都医科大学 | 吲哚生物碱衍生物、其制备方法及其用途 |
CN1743326A (zh) * | 2004-09-03 | 2006-03-08 | 首都医科大学 | 咔啉羧酸衍生物、其合成方法及其用途 |
CN102250202A (zh) * | 2010-05-19 | 2011-11-23 | 首都医科大学 | 1-对硝基苯基-β-咔啉-3-甲酰氨基酸苄酯及其合成方法和应用 |
-
2013
- 2013-06-05 CN CN201310225687.4A patent/CN104211700B/zh not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1743327A (zh) * | 2004-09-03 | 2006-03-08 | 首都医科大学 | 吲哚生物碱衍生物、其制备方法及其用途 |
CN1743326A (zh) * | 2004-09-03 | 2006-03-08 | 首都医科大学 | 咔啉羧酸衍生物、其合成方法及其用途 |
CN102250202A (zh) * | 2010-05-19 | 2011-11-23 | 首都医科大学 | 1-对硝基苯基-β-咔啉-3-甲酰氨基酸苄酯及其合成方法和应用 |
Also Published As
Publication number | Publication date |
---|---|
CN104211700A (zh) | 2014-12-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103159828B (zh) | 1-(4-羟基-3-甲氧羰基)-β-咔啉-3-甲酰色氨酰氨基酸苄酯、其合成及应用 | |
CN103450199B (zh) | 茶氨酸修饰的咔啉酰氨基酸苄酯、其制备、抗肿瘤活性和应用 | |
CN104211700B (zh) | 咔啉羧酸类似物,其合成,纳米结构,抗肿瘤活性和应用 | |
CN103450335B (zh) | β-咔啉酰色氨酰色氨酰氨基酸苄酯、其合成、抗肿瘤作用及应用 | |
CN106349148A (zh) | 具有抗肿瘤转移和抗炎活性的新型吲哚类化合物,其合成和应用 | |
CN105218637A (zh) | Lpniskp修饰的吲哚喹嗪,其制备,纳米结构,活性和应用 | |
CN105315332A (zh) | CIPPC-AA-OBzl,其制备,纳米结构,活性和应用 | |
CN109081801A (zh) | 酸性氨基酸修饰的吲哚乙醇衍生物,其合成,活性和应用 | |
CN103509011B (zh) | 1-(4-羟基-3-甲酰氨基酸基-苯基)-β-咔啉、制备、抗炎和抗肿瘤活性及应用 | |
Bu et al. | Cocrystallization-driven self-assembly with vanillic acid offers a new opportunity for surmounting fast and excessive absorption issues of antifungal drug 5-fluorocytosine: a combined theoretical and experimental research | |
CN108976159A (zh) | 芳香氨基酸修饰的吲哚乙醇衍生物,其合成,活性和应用 | |
CN105273050B (zh) | 咪唑并吡啶-6-甲酰-氨基酸苄酯,其合成,活性及应用 | |
KR102174196B1 (ko) | 소수성기가 도입된 실리콘-로다민 형광 프로브 및 이의 용도 | |
CN103450198B (zh) | 咪唑并吡啶并咪唑-3-取代乙酸苄酯、其合成、抗肿瘤活性及应用 | |
CN106146615A (zh) | 咪唑并吡啶-6-甲酰-氨基酸苄酯,其合成,活性和应用 | |
CN105294825B (zh) | 1-(乙基氨基酸苄酯)-β-咔啉-3-羧酸苄酯的纳米结构、制备、活性及应用 | |
CN108948137A (zh) | 3s-吲哚乙基-6s-极性氨基酸修饰的哌嗪-2,5-二酮,其合成,活性和应用 | |
CN105218623A (zh) | 1-(乙基氨基酸苄酯)-β-咔啉-3-羧酸苄酯,纳米结构,制备,活性及应用 | |
CN108929320A (zh) | 3r-吲哚甲基-6r-恶唑烷酮修饰的哌嗪-2,5-二酮,其合成,活性和应用 | |
CN110551120B (zh) | 6-氨基酰氨基正己酰咔啉羧酸苄酯,其制备,活性和应用 | |
CN112300246B (zh) | 天冬酰茶氨酸rgds修饰的5-氟尿嘧啶,其合成,活性和应用 | |
CN112390854B (zh) | 茶氨酸与rgds共同修饰的5-氟尿嘧啶,其合成,活性和应用 | |
CN105273044A (zh) | 1-(乙基氨基酸苄酯)-β-咔啉-3-羧酸苄酯、制备、纳米结构、活性和应用 | |
CN105273043A (zh) | 氨基酸苄酯修饰的β-咔啉,活性,纳米结构,合成及应用 | |
CN109456311A (zh) | 3r-吲哚甲基-6r-芳香氨基酸修饰的哌嗪-2,5-二酮,其合成,活性和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20160810 Termination date: 20210605 |